Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pioglitazone Hydrochloride in Diabetes Mellitus, Type 2: NCT04976283 Clinical Landscape Report 2026
16 October 2026
NCT04976283 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Orilanolimab(Syntimmune, Inc.) in Myasthenia Gravis: NCT04982289 Clinical Landscape Report 2026
16 October 2026
NCT04982289 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efgartigimod Alfa in Myasthenia Gravis: NCT04980495 Clinical Landscape Report 2026
16 October 2026
NCT04980495 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pentoxifylline in Metabolic Dysfunction Associated Steatohepatitis: NCT04977661 Clinical Landscape Report 2026
16 October 2026
NCT04977661 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Recombinant Human Coagulation Factor VIII (Takeda) in Hemophilia A: NCT04985682 Clinical Landscape Report 2026
16 October 2026
NCT04985682 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etavopivat in Beta-Thalassemia: NCT04987489 Clinical Landscape Report 2026
16 October 2026
NCT04987489 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sodium Phenylbutyrate/Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis: NCT04987671 Clinical Landscape Report 2026
16 October 2026
NCT04987671 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SHR-1906 in Idiopathic Pulmonary Fibrosis: NCT04986540 Clinical Landscape Report 2026
16 October 2026
NCT04986540 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TJ-68 in Muscle Cramp: NCT04998305 Clinical Landscape Report 2026
16 October 2026
NCT04998305 clinical landscape for Muscle Cramp: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Evetifator in Amyotrophic Lateral Sclerosis: NCT05006352 Clinical Landscape Report 2026
16 October 2026
NCT05006352 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AlloRx(Vitro Biopharma) in Amyotrophic Lateral Sclerosis: NCT05003921 Clinical Landscape Report 2026
16 October 2026
NCT05003921 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Censavudine in Frontotemporal Dementia: NCT04993755 Clinical Landscape Report 2026
16 October 2026
NCT04993755 clinical landscape for Frontotemporal Dementia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.